Stability of Oral Oxytocics in Tropical Climates - Results of Simulation Studies on Oral Ergometrine, Oral Methylergometrine, Buccal Oxytocin and Buccal Desamino-Oxytocin - EDM Research Series No. 012
(1994; 52 pages) Voir le document au format PDF
Table des matières
Afficher le documentAbbreviations
Afficher le documentSummary
Ouvrir ce répertoire et afficher son contenuIntroduction
Ouvrir ce répertoire et afficher son contenuMaterials and methods
Ouvrir ce répertoire et afficher son contenuResults
Ouvrir ce répertoire et afficher son contenuDiscussion
Afficher le documentConclusions and recommendations
Afficher le documentReferences
Fermer ce répertoireAnnexes
Afficher le documentAnnex 1: Ergometrine 0.2 mg tablets
Afficher le documentAnnex 2: Methylergometrine 0.125 mg tablets
Afficher le documentAnnex 3: Buccal oxytocin 200 IU
Afficher le documentAnnex 4: Buccal desamino-oxytocin, 50 IU
Afficher le documentAnnex 5: Summary of results
Afficher le documentAnnex 6: Figures 1 to 7
 

Annex 6: Figures 1 to 7

Figure 1. Stability of oral (methyl)ergometrine least and most harmful conditions

active ingredient (% of stated amount)

Figure 2. Stability of oral (methyl)ergometrine influence of humidity

active ingredient (% of stated amount)

Figure 3. Stability of oral (methyl)ergometrine influence of light

active ingredient (% of stated amount)

Figure 4. Stability of buccal (desamino)oxytocin least and most harmful conditions

active ingredient (% of stated amount)

Figure 5. Stability of buccal (desamino)oxytocin influence of humidity

active ingredient (% of stated amount)

Figure 6. Stability of buccal (desamino)oxytocin influence of light

active ingredient (% of stated amount)

Figure 7. Buccal OT, Dark, 30°, 75% influence of package

active ingredient (% of stated amount)

vers la section précédente
 
 
Le Portail d'information - Médicaments essentiels et produits de santé a été conçu et est maintenu par l'ONG Human Info. Dernière mise à jour: le 1 décembre 2019